Eli Lilly and Co. and its partner Acrux cannot stop competitors from selling generic versions of its testosterone treatment Axiron, a federal judge in Indianapolis ruled. Melbourne, Australia-based Acrux developed Axiron. Lilly, based in Indianapolis, has the exclusive rights to market the drug. The hormone replacement therapy product generated $29.3 million in global sales for the second quarter of 2016. The two companies filed a lawsuit last summer against a group of generic drugmakers including Perrigo Co., Actavis Laboratories and Lupin Pharmaceuticals, for infringing on their patent. U.S. Judge Sarah Evans Barker concluded that a formulation patent originally granted for the ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.